Retrospective evaluation of patients diagnosed with central precocious puberty who reached the final height

Basit Öğe Kaydı
dc.authoridbestas, asli/0000-0003-3289-6887
dc.authoridAktar Karakaya, Amine/0000-0001-7004-6803
dc.contributor.authorYaman, Kadri
dc.contributor.authorUnal, Edip
dc.contributor.authorBestas, Asli
dc.contributor.authorKarakaya, Amine Aktar
dc.contributor.authorBeyazit, Nurcan
dc.contributor.authorKolbasi, Baris
dc.date.accessioned2025-02-22T14:08:48Z
dc.date.available2025-02-22T14:08:48Z
dc.date.issued2024
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjectives Central precocious puberty (CPP) is the onset of puberty before the age of 8 in girls and 9 in boys. The primary goal of CPP treatment is control and arrest of puberty development. In this study, it was aimed to determine the factors associated with final height in patients who received gonadotropin-releasing hormone analogs (GnRHa) treatment and reached their final height.Methods From the medical records of the patients, age on admission, bone age (BA), weight-standard deviation score (SDS), height-SDS, BMI-SDS, target height-SDS, basal LH, FSH, E2, age at menarche, and pelvic USG findings were obtained.Results The mean age on admission of the 67 female patients was 7.5 +/- 0.60 years. On admission, 4.5 % of the patients were obese and 19.4 % were overweight. There was no difference between BMI-SDS at admission and after treatment. The mean age at menarche was 11.57 +/- 0.78 years. About 58.2 % of the patients reached the target height, 35.8 % exceeded the target height, and 6 % were below the target height. The mean height-SDS and predicted adult height (PAH) on admission were better in patients who exceeded the target height. It was determined that target height-SDS had a positive effect on delta height-SDS, while BA/CA ratio had a negative effect.Conclusions It was found that GnRHa treatment did not have a negative effect on BMI-SDS. It was shown that 94 % of the patients who received GnRHa treatment reached the target height, and in fact, 35.8 % exceeded the target height. A greater final height may be associated with good height-SDS and PAH values on admission.en_US
dc.identifier.doi10.1515/jpem-2024-0124
dc.identifier.endpage721en_US
dc.identifier.issn0334-018X
dc.identifier.issn2191-0251
dc.identifier.issue8en_US
dc.identifier.pmid38881279en_US
dc.identifier.scopus2-s2.0-85196526636en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage715en_US
dc.identifier.urihttps://doi.org/10.1515/jpem-2024-0124
dc.identifier.urihttps://hdl.handle.net/11468/29647
dc.identifier.volume37en_US
dc.identifier.wosWOS:001247412400001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherWalter De Gruyter Gmbhen_US
dc.relation.ispartofJournal of Pediatric Endocrinology & Metabolismen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzKA_WOS_20250222
dc.subjectcentral precocious pubertyen_US
dc.subjectfinal heighten_US
dc.subjectgonadotropin-releasing hormone analog treatmenten_US
dc.titleRetrospective evaluation of patients diagnosed with central precocious puberty who reached the final heighten_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu